These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 31106957

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
    Cauchie M, Toelen J, Peerlinck K, Jacquemin M.
    Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
    [Abstract] [Full Text] [Related]

  • 25. Monitoring standard and extended half-life products in hemophilia: Assay discrepancies for factor VIII and IX in pre- and postinfusion samples.
    Augustsson C, Norström E, Andersson NG, Zetterberg E, Astermark J, Strandberg K.
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1114-1120. PubMed ID: 33134777
    [Abstract] [Full Text] [Related]

  • 26. Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.
    Suzuki A, Suzuki N, Kanematsu T, Okamoto S, Suzuki N, Tamura S, Kikuchi R, Katsumi A, Kojima T, Matsushita T.
    Int J Lab Hematol; 2024 Aug; 46(4):705-713. PubMed ID: 38426662
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.
    Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ.
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D, Toelen J, Schoeters J, Van Horenbeeck I, Vanlinthout I, Debasse M, Peerlinck K, Jacquemin M.
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [Abstract] [Full Text] [Related]

  • 31. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq® ) in adults with severe haemophilia A: efficacy and safety.
    Lissitchkov T, Hampton K, von Depka M, Hay C, Rangarajan S, Tuddenham E, Holstein K, Huth-Kühne A, Pabinger I, Knaub S, Bichler J, Oldenburg J.
    Haemophilia; 2016 Mar; 22(2):225-231. PubMed ID: 26315974
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C, Oldenburg J, Ettingshausen CE, Tiede A, Khair K, Négrier C, Klamroth R.
    Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
    Sandberg H, Kannicht C, Stenlund P, Dadaian M, Oswaldsson U, Cordula C, Walter O.
    Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
    [Abstract] [Full Text] [Related]

  • 36. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.
    Klukowska A, Szczepański T, Vdovin V, Knaub S, Jansen M, Liesner R.
    Haemophilia; 2016 Mar; 22(2):232-239. PubMed ID: 26370328
    [Abstract] [Full Text] [Related]

  • 37. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
    Mathias M, Abraham A, Belletrutti MJ, Carcao M, Carvalho M, Chambost H, Chan AKC, Dubey L, Ducore J, Gattens M, Gresele P, Gruel Y, Guillet B, Jiménez-Yuste V, Kitanovski L, Klukowska A, Lohade S, Mancuso ME, Oldenburg J, Pollio B, Sigaud M, Vilchevska K, Wu JKM, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.
    Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Functional characteristics of N8, a new recombinant FVIII.
    Christiansen ML, Balling KW, Persson E, Hilden I, Bagger-Sørensen A, Sørensen BB, Viuff D, Segel S, Klausen NK, Ezban M, Lethagen S, Steenstrup TD, Kjalke M.
    Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.